Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118009 | 0.89 | KMT2A (0.64) | CA1CA2CA12CA9LMNA | |
| SCHEMBL9781942 | 0.84 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL7995893 | 0.84 | ESR1 (0.62) | ESR1LMNACYP1A2CYP3A4SMN1; SMN2 | |
| SCHEMBL12674759 | 0.83 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2214078 | 0.83 | CA12 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL378575 | 0.82 | LOXL2 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL128190 | 0.81 | CA1 (0.70) | CA1CA2CA12CA7CA9 | |
| SCHEMBL87450 | 0.81 | CA1 (0.83) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1198816 | 0.81 | CYP4F2 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12199135 | 0.80 | CA1 (0.68) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398326-B2 | Monoazo dichroic dye compound, polarizing plate composition comprising same, polarizing plate formed therefrom, and optical device comprising same | LG CHEM, LTD. (KR) | 2025-08-26 | — | — | US | disclosed |
| US-20230357638-A1 | MONOAZO DICHROIC DYE COMPOUND, POLARIZING PLATE COMPOSITION COMPRISING SAME, POLARIZING PLATE FORMED THEREFROM, AND OPTICAL DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357638-A1 | MONOAZO DICHROIC DYE COMPOUND, POLARIZING PLATE COMPOSITION COMPRISING SAME, POLARIZING PLATE FORMED THEREFROM, AND OPTICAL DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4234552-A2 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116535285-A | Photocatalytic benzyl position C (sp 3 ) Method for functionalization of Cl bonds and use thereof | 中国科学院理化技术研究所 | 2023-08-04 | — | — | CN | disclosed |
| EP-3426244-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3426244-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116057429-A | Monoazo dichroic dye compound, polarizing plate composition comprising the same, polarizing plate formed therefrom, and optical device comprising the same | 株式会社LG化学 | 2023-05-02 | — | — | CN | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-7351719-B2 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-0303478-B1 | IMPROVEMENTS IN OR RELATING TO LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4820723-A | FOR TREATMENT OF HYPERSENSITIVITY, ASTHMA, SHOCK OR CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0303478-A1 | Improvements in or relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1989-02-15 | — | — | EP | disclosed |
| US-4735959-A | HYPOGLYCEMIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CA1 1552/4885CA2 806/4885CA12 1863/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CA1 4351/4885CA2 952/4885CA12 3074/4885 |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | CHRM1, CHRM2, CHRM3 | CA1 4458/4885CA2 3223/4885CA12 3500/4885 |
| US-20040152742-A1 | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds | MCHR2, MCHR1, NPY1R | CA1 4048/4885CA2 1732/4885CA12 3083/4885 |
| US-20050261286-A1 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | CHRM1, CHRM2, CHRM3 | CA1 4458/4885CA2 3223/4885CA12 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.